Back-to-back publications in the February issue of Nature Genetics reveal the identity of the gene underlying the thirteenth, and arguably most severe, Fanconi anemia (FA) complementation group: biallelic mutations in PALB2 cause FA complementation group N (FA-N). A third publication in the same issue further exemplifies the importance of this ‘maintenance of genomic stability’ pathway in the general (non-FA) population; like FANCD1/BRCA2 and FANCJ/BRIP1, heterozygosity for FANCN/PALB2 mutations is associated with an increased susceptibility to breast cancer.
FA is a rare autosomal and X-linked recessive disorder characterized by developmental abnormalities, progressive bone marrow failure and a pronounced susceptibility to cancer.1 FA was first described by Swiss pediatrician Guido Fanconi in 1927, when he encountered three brothers afflicted with aplastic anemia as well as congenital anomalies, including microcephaly and skin hyper-pigmentation. Decades of FA research led Fanconi to hypothesize that mutation of a single gene could not account for the clinical heterogeneity observed among FA patients. Eighty years later, Fanconi's astute observation resonates; to date, FA has been associated with mutation of any one of 12 different genes. Encoded by these genes includes a core multi-protein E3 ubiquitin ligase (comprising FANC proteins A, B, C, E, F, G, L and M), a substrate (FANCD2) and three ‘downstream’ proteins (FANCD1/BRCA2, FANCJ/BRIP1 and now FANCN/PALB2).
The following model for the FA pathway has been proposed: after exposure to DNA damaging agents, as well as during S phase of the cell cycle, the core FA complex catalyzes the monoubiquitination of the FANCD2 protein (Figure 1). Monoubiquitination of FANCD2 signals its translocation to discrete nuclear foci, where it colocalizes with the DNA repair proteins BRCA1 and Rad51.2 Monoubiquitination of FANCD2 also appears to promote the loading of BRCA2 into chromatin.3 Thus, it seems likely that the FA proteins function cooperatively in the maintenance of genomic stability by promoting the repair of damaged DNA via a homologous recombination (HR)-mediated mechanism. On the face of it, the identification of FANCN indeed supports this hypothesis.
FANCN (a.k.a. PALB2 for ‘Partner and Localizer of BRCA2’), the latest addition to the ever-lengthening list of FA proteins, was recently identified by Xia et al4 in a screen to uncover novel BRCA2-interacting proteins. PALB2 and BRCA2 were found to stably associate in chromatin. PALB2 binds to the N terminus of BRCA2 and is required for the intra-nuclear localization and stabilization of BRCA2. Thus, PALB2 facilitates BRCA2's previously established roles in the S phase checkpoint response and in HR-mediated DNA double-strand break repair.4, 5
Notably, PALB2-depleted cells are also hypersensitive to the DNA crosslinking agent mitomycin C (MMC),4 a hallmark phenotype of FA patient cells. This finding, coupled with the fact that biallelic BRCA2 mutations underlie FA complementation group D1 (FA-D1),6 fueled PALB2's candidacy as a bona fide new FA gene. Thus, Xia et al7 examined cells from unassigned FA patient EUFA1341 for PALB2 protein expression. Serendipitously, full-length PALB2 protein was not detected in EUFA1341 cells. Consistent with their initial observations of a role for PALB2 in the stabilization of BRCA2 in chromatin, EUFA1341 cells lacked chromatin-bound BRCA2. Genomic and cDNA sequencing subsequently uncovered biallelic PALB2 mutations in EUFA1341. Reintroduction of wild-type PALB2 into EUFA1341 stabilized BRCA2 in the nucleus and corrected the MMC sensitivity of these cells. Intriguingly, Xia et al describe a MMC-resistant clone of EUFA1341 that most likely arose via a spontaneous Alu-mediated recombination event on the maternal chromosome arm harboring the mutant PALB2 allele, 16p12. This intra-chromosomal recombination event deleted PALB2 exon 4, which contained a nonsense stop mutation, and restored expression of a partially functional protein capable of promoting BRCA2's nuclear functions.
Supporting the findings of Xia et al, a second independent report by Reid et al8 describe biallelic PALB2 mutations in an additional seven unassigned FA patients. PALB2 protein expression could not be detected in cells from four of these patients, and reintroduction of wild-type PALB2 into one patient line restored PALB2 protein expression and corrected the MMC-induced G2/M accumulation of these cells. Collectively, these reports firmly establish PALB2 as FANCN.
Downstream divergence?
Classic FA is characterized by progressive bone marrow failure with a predisposition for squamous cell carcinoma (SCC) of the head and neck and anogenital regions later in life. The median age of onset for FA patient SCC is 31 years.9 The clinical phenotype of FA-N patients is, however, strikingly different, and eerily resembles that of FA-D1 patients.10 All eight FA-N patients developed aggressive embryonal tumors in early childhood including medulloblastoma and Wilms' tumor. Five FA-N patients developed tumors under the age of 2 years. So, while sharing some classic FA clinical manifestations, including hypoplastic thumbs and growth retardation, FA complementation groups D1 and N are clearly unique, possibly warranting their clinical sub-classification.
In a third report in the same issue, Nazeem Rahman and colleagues demonstrate that monoallelic truncating PALB2 mutations are associated with an approximate two-fold increased risk of familial breast cancer, representing another point of divergence. To date, mutations in only the three ‘downstream’ (of FANCD2 monoubiquitination) FA genes, FANCD1/BRCA2, FANCJ/BRIP1, and FANCN/PALB2, have now been clearly associated with an increased risk for breast cancer.11, 12
Several important cellular features also distinguish FA-D1 and FA-N patient cells from cells from all other FA complementation groups. These include phenotypes of considerable recent debate, including the ability of FA cells to form Rad51 nuclear foci,3, 13, 14, 15 and consequently, the role of the FA pathway in HR DNA repair. Rad51 is the major mammalian DNA-strand recombinase. The Rad51 protein forms a nucleoprotein filament on single-stranded DNA and catalyzes strand invasion of a homologous intact sister chomatid during the conservative ‘gene conversion’ pathway of HR repair (Figure 2). The influence of the upstream FA proteins (A, B, C, E, F, G, L and M), as well as FANCD2, on the stabilization of Rad51 in nuclear foci is ambiguous.3, 13, 14, 15 However, cells from FA-D1 and FA-N patients' display severely attenuated Rad51 nuclear foci formation.7, 8, 14 Furthermore, FANCD1/BRCA2 and FANCJ/BRIP1, and now FANCN/PALB2, all appear to be required for the gene conversion-mediated repair of a DNA double-strand break.4, 5, 16 The role of the other FA proteins in this process is tenuous.15, 17
The devil may be in the details
While the upstream FA proteins, as well as FANCD2, may not function directly in gene conversion HR repair, it seems likely that they at least cooperatively promote this conservative, error-free DNA repair pathway under certain conditions (Figure 2). Conversely, FA proteins FANCD1/BRCA2 and FANCN/PALB2, and possibly FANCJ/BRIP1, function directly in this mode of DNA repair. The increased clinical severity of FA-D1 and FA-N may be a consequence of these proteins functioning ‘beyond a point of no return’, that is, following a cellular commitment to a doomed gene conversion HR repair mechanism. Furthermore, many DNA lesions, and not solely the DNA crosslink, will be repaired via a DNA double-strand break intermediate, necessitating their function. Nevertheless, in the absence of an intact FA pathway, non-conservative, error-prone DNA repair pathways, such as single-strand annealing or inter-chromosomal HR, may predominate. The former pathway would be expected to give rise to intra-chromosomal deletions, possibly due to recombination between mobile repetitive sequences such as Alu elements (see EUFA1341 reversion event above). Indeed, an increased frequency of deletion mutations at the HPRT locus in FA lymphoblasts was described by Papadopoulo et al18 many years ago. Furthermore, failed inter-chromosomal recombination events may underlie the trademark FA cytogenetic anomalies, the tri- and quadri-radial chromosome formations.
While many mechanistic details remain to be resolved, what is clear is that our continued research into this rare debilitating disease continues to have far-reaching implications for our understanding of cancer susceptibility in the general (non-FA) populationâ–ª
References
Taniguchi T, D'Andrea AD : Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107: 4223–4233.
Garcia-Higuera I, Taniguchi T, Ganesan S et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001; 7: 249–262.
Wang X, Andreassen PR, D'Andrea AD : Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004; 24: 5850–5862.
Xia B, Sheng Q, Nakanishi K et al: Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719–729.
Moynahan ME, Pierce AJ, Jasin M : BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263–272.
Howlett NG, Taniguchi T, Olson S et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606–609.
Xia B, Dorsman JC, Ameziane N et al: Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007; 39: 159–161.
Reid S, Schindler D, Hanenberg H et al: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162–164.
Kutler DI, Auerbach AD, Satagopan J et al: High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106–112.
Hirsch B, Shimamura A, Moreau L et al: Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004; 103: 2554–2559.
Rahman N, Seal S, Thompson D et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165–167.
Seal S, Thompson D, Renwick A et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38: 1239–1241.
Digweed M, Rothe S, Demuth I et al: Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002; 23: 1121–1126.
Godthelp BC, Wiegant WW, Waisfisz Q et al: Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006; 594: 39–48.
Ohashi A, Zdzienicka MZ, Chen J, Couch FJ : Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. J Biol Chem 2005; 280: 14877–14883.
Litman R, Peng M, Jin Z et al: BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8: 255–265.
Nakanishi K, Yang YG, Pierce AJ et al: Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci USA 2005; 102: 1110–1115.
Papadopoulo D, Guillouf C, Mohrenweiser H, Moustacchi E : Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus. Proc Natl Acad Sci USA 1990; 87: 8383–8387.
Author information
Authors and Affiliations
Corresponding author
Additional information
Note added in proof
The author wishes to acknowledge that since going to press two new publications have revealed the identity of the FANCI gene as KIAA1794, encoding a previously uncharacterized FANCD2 paralog.
Rights and permissions
About this article
Cite this article
Howlett, N. Fanconi Anemia: Fanconi anemia, breast and embryonal cancer risk revisited. Eur J Hum Genet 15, 715–717 (2007). https://doi.org/10.1038/sj.ejhg.5201860
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5201860
This article is cited by
-
Breast cancer susceptibility: current knowledge and implications for genetic counselling
European Journal of Human Genetics (2009)
-
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
Breast Cancer Research and Treatment (2009)